癌症研究
MAPK/ERK通路
体内
下调和上调
纤维化
上皮-间质转换
医学
化学
信号转导
病理
生物
细胞生物学
生物化学
基因
生物技术
作者
Fenfen Peng,Hongyu Li,Shuting Li,Yuxian Wang,Wenting Liu,Wangqiu Gong,Bohui Yin,Sijia Chen,Ying Zhang,Congwei Luo,Weidong Zhou,Yihua Chen,Peilin Li,Qianyin Huang,Zhaozhong Xu,Haibo Long
标识
DOI:10.1038/s41374-019-0245-6
摘要
Micheliolide (MCL), derived from parthenolide (PTL), is known for its antioxidant and anti-inflammatory effects and has multiple roles in inflammatory diseases and tumours. To investigate its effect on renal disease, we intragastrically administrated DMAMCL, a dimethylamino Michael adduct of MCL for in vivo use, in two renal fibrosis models-the unilateral ureteral occlusion (UUO) model and an ischaemia-reperfusion injury (IRI) model and used MCL in combination with transforming growth factor beta 1 (TGF-β1) on mouse tubular epithelial cells (mTEC) in vitro. The expression of fibrotic markers (fibronectin and α-SMA) was remarkably reduced, while the expression of the epithelial marker E-cadherin was restored after DMAMCL treatment both in the UUO and IRI mice. MCL function in TGF-β1-induced epithelial-mesenchymal transition (EMT) in mTEC was consistent with the in vivo results. Metadherin (Mtdh) was activated in the fibrotic condition, suggesting that it might be involved in fibrogenesis. Interestingly, we found that while Mtdh was upregulated in the fibrotic condition, DMAMCL/MCL could suppress its expression. The overexpression of Mtdh exerted a pro-fibrotic effect by modulating the BMP/MAPK pathway in mTECs, and MCL could specifically reverse this effect. In conclusion, DMAMCL/MCL treatment represents a novel and effective therapy for renal fibrosis by suppressing the Mtdh/BMP/MAPK pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI